BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost, Rinske; Dhillon, Kiranjit K; van der Gulden, Hanneke; van der Heijden, Ingrid; Brandsma, Inger; Cruz, Cristina; Chondronasiou, Dafni; Castroviejo-Bermejo, Marta; Boon, Ute; Schut, Eva; van der Burg, Eline; Wientjens, Ellen; Pieterse, Mark; Klijn, Christiaan; Klarenbeek, Sjoerd; Loayza-Puch, Fabricio; Elkon, Ran; van Deemter, Liesbeth; Rottenberg, Sven; van de Ven, Marieke; ... (2016). BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Journal of clinical investigation, 126(8), pp. 2903-2918. American Society for Clinical Investigation 10.1172/JCI70196

Preview

Text JCI70196.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview

Heterozygous germline mutations in breast cancer 1 (BRCA1) strongly predispose women to breast cancer. BRCA1 plays an important role in DNA double-strand break (DSB) repair via homologous recombination (HR), which is important for tumor suppression. Although BRCA1-deficient cells are highly sensitive to treatment with DSB-inducing agents through their HR deficiency (HRD), BRCA1-associated tumors display heterogeneous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinical trials. It is unclear whether all pathogenic BRCA1 mutations have similar effects on the response to therapy. Here, we have investigated mammary tumorigenesis and therapy sensitivity in mice carrying the Brca1185stop and Brca15382stop alleles, which respectively mimic the 2 most common BRCA1 founder mutations, BRCA1185delAG and BRCA15382insC. Both the Brca1185stop and Brca15382stop mutations predisposed animals to mammary tumors, but Brca1185stop tumors responded markedly worse to HRD-targeted therapy than did Brca15382stop tumors. Mice expressing Brca1185stop mutations also developed therapy resistance more rapidly than did mice expressing Brca15382stop. We determined that both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells expressed a really interesting new gene domain-less (RING-less) BRCA1 protein that mediated resistance to HRD-targeted therapies. Together, these results suggest that expression of RING-less BRCA1 may serve as a marker to predict poor response to DSB-inducing therapy in human cancer patients.

Interest & Impact

Downloads

201 since deposited on 10 Jul 2017
26 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item